Merck’s 2025 Year-End Analysis: A $70 Billion Vision for the Future Merck (MRK) closed 2025 with a strong 16.4billionfourthquarter∗∗,drivenbythecontinueddominanceof∗∗Keytruda∗∗andtherapiduptakeofnewlauncheslike∗∗Winrevair∗∗.Despiteheadwindsintheinternationalvaccinemarket,thecompanyhasdoubleddownonitsfuture,revealingamassive∗∗70 billion…